Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 20Sarcoma 4Neuroendocrine Tumors 4Neoplasms 4Carcinoma, Medullary 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Kidney Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Adenocarcinoma, Follicular 2Wilms Tumor 1Urologic Neoplasms 1

Interventions

Sunitinib 2tucatinib 1testosterone 17 beta-cypionate 1pembrolizumab 1dodecyl maltoside 1cabozantinib 1Urinary Diversion 1Trastuzumab 1Testosterone Propionate 1Standard of Care 1Saline Solution 1Radiosurgery 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Methyltestosterone 1Lidocaine 1Immune Checkpoint Inhibitors 1Fulvestrant 1Doxycycline 1Cystectomy 1Control Groups 1Ado-Trastuzumab Emtansine 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urologic Neoplasms × cabozantinib × Clear all
NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡